Needham & Company
-
Notable Analyst Rating Changes 03/05: (MTG) (APOL) (YHOO) Upgraded; (WPZ) (AAPL) (IPXL) Downgraded
-
StreetInsider.com Pre-Open Movers 03/05: (ZOLT) (APP) (MTG) Higher; (IPXL) (JCP) (FR) Lower (more...)
-
Needham & Company Maintains a 'Buy' on Warner Chilcott (WCRX); Loses Appeal
-
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Detrol LA Settlement Provides Small Dose of Certainty
-
Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too
-
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Concentrating Hard...On FDA Warning Letter Effects
-
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Clearing Q1 Hurdle; Regulatory Clouds Remain
-
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Chalk One Up in the PIV Win Column As Doryx Goes Generic
-
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Adderall XR Supply Issues Turn Positive, Leading to Solid 4Q11 EPS Beat
-
Needham & Company on Impax Labs (IPXL): Not a Strategic Game-Change but Zomig Offsets SG&A Ramp and Provides Short-Term EPS Boost
-
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Adderall XR Supply Issue Rears its Ugly Head but OpEx Leverage Still Allows 3Q11 EPS to Beat
-
Notable Analyst Rating Changes 06/08: (BOBE) (EBAY) (VZ) Upgraded; (IPXL) (QNST) (SPWRA) Downgraded
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Warning Letter Could Complicate “Sweetest” Doryx 150mg Settlement Outcomes
-
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); FDA Warning Letter Puts The Brakes On New Approvals For Now Though We See Little Lasting Impact
-
Notable 52-Week Highs and Lows of the Day 03/15: (IPXL) (PAY) (WSM) High; (NOK) (AOB) (GM) Low
-
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Branded Platform Still Remains A “Show-Me” Story
-
Needham & Company on Impax Labs (IPXL); Lawsuit Appears to Confirm That Generic Concerta Opportunity Remains A Real But Distant Star On Horizon
-
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Receives Final Approval for Generic Oracea Potentially Setting Up Exclusivity Launch
-
Needham & Company Initiates Coverage on Impax Laboratories (IPXL) with a Hold
-
Needham & Company Initiates Coverage on Impax Laboratories (IPXL) with a Hold
-
Notable Analyst Rating Changes 1/8: HAL, AMAT, JCP, AGU, ESV, RDN, More Upgraded; M, KO, STX, ERIC, WEN, PCS, More Downgraded